Skip to main content
AU Proudly Based in Australia
Research Use Only | Lab Tested | Secure Checkout
HomePeptidesBundlesResearch AreasQualityResourcesContact
Research Grade Quality Independently Tested

Semaglutide

≥ 99% (HPLC) CAS 910463-68-2 C₁₈₇H₂₉₁N₄₅O₅₉ Verified Synthesis Batch COA Available

$89.99

Size / Strength

HPLC Verified
COA Included
Fast Dispatch
Discreet Shipping
100% Quality Guarantee

Every batch of Semaglutide is independently third-party tested. 30-day money-back guarantee — no questions asked.

≥ 99% Purity Verified
HPLC Tested & Verified
Cold Chain Temperature Controlled
Next Day Fast & Discreet

Semaglutide – Research Overview

Semaglutide is a research-grade compound supplied for laboratory use only.

Research Use Only

This product is intended solely for laboratory research purposes. Not for human consumption.

Semaglutide – Storage & Handling

Correct storage is essential for maintaining the stability and purity of Semaglutide. Follow the guidance below for both the lyophilised (freeze-dried) powder and any reconstituted solution.

  • Store lyophilised powder at 2–8°C (refrigerated), protected from light
  • For longer-term storage, keep frozen at -20°C in the original sealed vial
  • Once reconstituted, refrigerate at 2–8°C and use within 30 days
  • Avoid repeated freeze-thaw cycles once reconstituted
  • Shelf life of 24 months from manufacture date when stored correctly

Semaglutide – Technical Specifications

Every batch of Semaglutide is independently analysed before dispatch. The values below describe the current research batch.

Product NameSemaglutide
CAS Number910463-68-2
Molecular FormulaC₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight4113.58 g/mol
Quantity / Strength5mg | 10mg | 20mg
Purity ≥ 99% (HPLC)
FormLyophilised Powder
AppearanceWhite Lyophilised Powder
Batch NumberPA-0046
Storage Conditions2°C-8°C (Refrigerated)
CategoryWeight Loss
Intended UseResearch Use Only — not for human consumption

Semaglutide – Certificate of Analysis

Every batch of Semaglutide is independently tested before dispatch. View the full COA for the current batch below.

Certificate of Analysis (COA)

Batch Number PA-0046

≥ 99% Purity HPLC
Confirmed Identity Mass Spec
Pass Heavy Metals ICP-MS

Research Disclaimer

For Research Use Only — Not for Human Consumption

This content is provided for educational, scientific and research-information purposes only. It does not provide medical advice, treatment recommendations or personal dosage instructions. Semaglutide has been investigated extensively in preclinical and clinical research, but the regulatory status, safety, efficacy and approved uses of registered semaglutide medicines should not be attributed to unregistered or research-grade products.

  • Not for human or veterinary use
  • No claims are made regarding safety or efficacy in humans
  • Must be handled with appropriate laboratory safety equipment
  • Purchaser assumes all responsibility for legal, compliant use

References

5 sources
  1. 1
    Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375(19):1834-1844.PubMed: https://pubmed.ncbi.nlm.nih.gov/27633186/
  2. 2
    Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.PubMed: https://pubmed.ncbi.nlm.nih.gov/33567185/
  3. 3
    Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial. The Lancet. 2021;397(10278):971-984.PubMed: https://pubmed.ncbi.nlm.nih.gov/33667417/
  4. 4
    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221-2232.PubMed: https://pubmed.ncbi.nlm.nih.gov/37952131/
  5. 5
    Australian Government, Therapeutic Goods Administration (TGA). Compounding Safety Information: Semaglutide-Like Products. Therapeutic Goods Administration. 15 December 2023.TGA: https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/compounding-safety-information-semaglutide-products

Citations are provided for research reference and open in a new tab. Listing a study does not imply it evaluated this specific product.

Semaglutide – Frequently Asked Questions

Stay Updated with New Research
and Exclusive Offers

Subscribe to our newsletter for the latest product updates, research insights and exclusive promotions.

We respect your privacy. Unsubscribe anytime.

Why Researchers Choose Us

Research-Grade Quality. Trusted by Researchers Across Australia.

Learn About Our Quality
Discreet Packaging
Fast Australia-Wide Delivery
Expert Support
30-Day Money Back